Table 2

a) Responders
	Sex	Age	PsA	Previous biological treatment	Current treatment	Weeks of treatment	IFX 0	IFX 2	IFX 4	IFX 6	IFX 7	IFX 8	ATI
1.	M	66	no	no	infliximab + MTX 7.5	230	2.31	8.08	4.65	1.55	1.13	0.81	negative
2.	M	58	no	efalizumab	infliximab	246	2.2	11.13	4.43	3.79	1.95	1.8	negative
3.	M	56	no	etanercept	infliximab	118	3.13	15.65	7.76	5.4	5.1	4.04	negative
4.	M	59	no	no	infliximab	62	1.41	6.96	4.21	2.5	1.55	1.05	negative
5.	M	50	no	efalizumab	infliximab	158	1.15	5.25	4.18	1.8	0.89	0.77	negative
6.	F	24	no	etanercept	infliximab	134	1.35	16.25	6.42	2.96	1.73	0.61	negative
7.	M	60	yes	efalizumab	infliximab + MTX 15	316	1.35	10.13	5.64	4.19	1.94	1.18	negative
8.	M	49	yes	no	infliximab+ MTX 10 + KS	230	3.04	6.36	2.37	1.2	1.15	1.05	negative
9.	F	48	no	no	infliximab	54	1.16	6.58	2.32	1.44	1.16	0.69	negative
10.	F	60	no	etanercept	infliximab	174	3.88	6.62	2.67	1.57	1.16	0.88	negative
11.	M	41	no	no	infliximab	238	2.16	27.67	6.78	3.19	2.18	1.95	negative
12.	M	34	no	no	infliximab	22	3.45	15.56	9.54	4.82	3.12	2.84	negative
13.	M	63	no	no	infliximab + MTX 7.5	342	0.55	11.71	3.23	2.01	1.11	0.73	negative
14.	M	32	no	efalizumab	infliximab	158	1.66	7.15	3.78	1.58	1.29	1.41	negative
15.	M	49	no	efalizumab	infliximab	326	1.22	6.59	3.46	1.92	1.17	1.32	negative
16.	M	62	no	ustekinumab	infliximab	62	1.86	12.78	4.55	2.47	3.1	1.26	negative
17.	M	53	no	adalimumab	infliximab	46	0.4	23.49	8.61	2.72	1.92	1.01	negative
b) Partial responders
	Sex	Age	PsA	Previous biological treatment	Current treatment	Weeks of treatment	IFX 0	IFX 2	IFX 4	IFX 6	IFX 7	IFX 8	ATI
18.	F	37	yes	no	infliximab + KS	134	0	3.24	1.02	0.85	0.31	0	41.553
19.	M	53	no	etanercept, adalimumab	infliximab	22	0	3.48	0.5	0.14	0	0	504.243
20.	M	56	no	no	infliximab	30	0	3.32	0.9	0	0	0	169.771
21.	M	58	no	etanercept	infliximab	182	0	2.82	0.68	0	0	0	1270.963
22.	M	55	yes	no	infliximab	30	0	2.47	0.58	0	0	0	628
23.	M	32	no	efalizumab	infliximab	166	0.2	2.2	1.16	0.46	0.41	0.35	negative
24.	M	60	no	etanercept	infliximab	138	0	1.92	1.13	0.23	0.11	0	negative
c) Non-responders
	Sex	Age	PsA	Previous biological treatment	Treatment	Weeks of treatment	IFX 0	IFX 2	IFX 4	IFX 6	IFX 7	IFX 8	ATI
25.	F	54	no	etanercept	infliximab	166	3.94	10.61	4.92	4.26	2.39	1.53	negative

Table 2: Dynamics of IFX levels and the presence of antibodies to infliximab in serum of patients with psoriasis treated with infliximab. IFX0–week 0., IFX2–week 2., IFX4– week 4., IFX6–week 6., IFX7–week 7., IFX8–week 8., IFX in ug/ml, ATI in IU/ml.